How SOLARAZE® Gel Works
SOLARAZE® Gel contains the active ingredient diclofenac sodium, which is a type of medicine called a non-steroidal anti-inflammatory drug (NSAID). These drugs are commonly used in many areas of medicine. NSAIDs are known to provide both anti-inflammatory and anti-neoplastic (anti-cancer) benefits.
It is not fully understood how SOLARAZE® Gel works in treating actinic keratoses, but it is proven to be both effective and safe.
In a clinical study, people used SOLARAZE® Gel twice a day for 90 days and there was a steady decrease in the number of AKs throughout the treatment period. At the end of treatment, few AKs remained and what's more, people continued to see improvement over the next 30 days even after they had stopped using SOLARAZE® Gel. There was a 90% clearance of AKs 30 days after finishing treatment.
Important Product Safety Information
SOLARAZE® (diclofenac sodium-3%) Gel is indicated for the topical treatment of actinic keratoses (AKs).
Sun avoidance is indicated during SOLARAZE® Gel therapy. The safety of using sunscreens, cosmetics or topical medications while being treated with SOLARAZE® Gel is not known. Do not get SOLARAZE® Gel into eyes.
As with other non-steroidal anti-inflammatory drugs (NSAIDs), severe allergic reactions may occur in patients without prior exposure to diclofenac. Patients who are allergic or sensitive to aspirin and/or other NSAIDs, who also have asthma and nasal polyps, may have a condition known as the aspirin triad and should tell their doctor before beginning therapy.
SOLARAZE® Gel should be used with caution in patients with active stomach ulcers or bleeding and severe kidney or liver impairments. SOLARAZE® Gel should not be applied to open wounds, skin infections or any skin that shows signs of irritation.
In clinical trials, the most common adverse reactions involved the skin and included contact dermatitis, rash, dry skin and exfoliation (widespread reddened and peeling skin).
SOLARAZE® (diclofenac sodium-3%) Gel Full Prescribing Information.
